Wed, Apr 30, 8:25 PM (15 days ago)
**Catheter Precision, Inc. (VTAK) 10-K/A Summary** **Company Overview:** Catheter Precision, Inc. (VTAK) is a medical device company focused on innovative solutions. The 10-K/A amendment primarily updates Part III, Item 13, detailing related party transactions and director independence. **Financial Performance:** - **Revenue and Net Income:** Specific financial figures for revenue, net income, and operating expenses are not provided in the amendment. For detailed financials, refer to the original 10-K filing. - **Earnings Per Share (EPS):** Not explicitly mentioned in the amendment. **Strategic Overview:** - **Related Party Transactions:** The amendment includes detailed information on transactions with related parties, such as executive officers, directors, and significant shareholders. Key transactions involve stock options, warrants, and loans. - **Director Independence:** The board reviewed and confirmed the independence of directors, ensuring compliance with NYSE American rules. **Future Outlook:** - **Acquisition of Cardionomic Assets:** VTAK is pursuing the acquisition of certain assets from Cardionomic, Inc., which could expand its product portfolio. The acquisition is subject to closing conditions and financing. - **Financing Needs:** The company anticipates needing additional financing to develop the acquired assets and maintain liquidity. **Risk Factors:** - **Financial Risks:** VTAK faces risks related to liquidity, profitability, and the ability to secure additional financing. - **Operational Risks:** Dependence on key personnel, regulatory compliance, and supply chain management are critical operational risks. - **Market Risks:** Competition in the medical device industry and potential changes in trade policies could impact financial performance. **Financial Condition:** - **Liquidity:** The company does not have sufficient liquidity without additional financing or strategic transactions. - **Debt:** VTAK has outstanding loans from related parties, with amended terms extending maturity dates and increasing interest rates. **Market Position Changes:** - **Stock Performance:** The aggregate market value of common stock held by non-affiliates was approximately $3.9 million as of June 30, 2024. - **Shareholder Structure:** As of March 17, 2025, VTAK had 9,268,632 shares of common stock outstanding. **Conclusion:** VTAK's 10-K/A amendment provides crucial updates on related party transactions and director independence. The company is strategically positioning itself for growth through potential acquisitions and financing efforts, while navigating significant financial and operational risks. Investors should closely monitor the company's ability to secure additional financing and successfully integrate acquired assets.